Skip to content

Schering-Plough SGP Stock-Based Comp

Stock-Based Comp at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$300M+4.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$257.4M+0.7%
Glaukos logo
GlaukosGKOS
$19.14M+47.4%
AbbVie logo
AbbVieABBV
$444M+8.3%
Bausch + Lomb logo
Bausch + LombBLCO
$34M+21.4%
HRO
HarrowHROW
$3.84M-15.8%

Segments

By segment

See full
Reporting Segment$2.79M+87.1%

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's stock-based comp?
Schering-Plough (SGP) reported stock-based comp of $1.68M in Q1 2026.
How has Schering-Plough's stock-based comp changed year-over-year?
Schering-Plough's stock-based comp increased by 385.5% year-over-year, from $345K to $1.68M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.